Marbocyl

Marbocyl™ 10% Solution for Injection

Presentation

Solution for Injection. Each 100ml contains marbofloxacin 10g, monothioglycerol 0.1g, metacresol 0.2g and disodium edetate 0.01g

Uses

In cattle: Indicated in the treatment of respiratory infections caused by susceptible strains of organisms. It is also indicated in the treatment of acute E.coli mastitis.

In pigs: Indicated in the treatment of Metritis Mastitis Agalactia syndrome caused by susceptible strains of organisms.

Dosage and administration

The recommended dose rate is 2mg/kg/day (1ml/50kg) in a single daily injection by intramuscular, subcutaneous or intravenous routes in cattle and by intramuscular route in pigs.

Treatment durations are 3 days in pigs and 3 to 5 days in cattle.

In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.

Contra-indications, warnings, etc

Withdrawal periods

Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from cattle after 36 hours from the last treatment.

Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 6 days from the last treatment. Pigs may be slaughtered for human consumption only after 4 days from the last treatment.

Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.

General precautions: No severe side-effects are to be expected at doses up to 3 or 5 times the recommended dose in cattle and pigs respectively. In particular, no lesions of the articular joints are encountered.

Intramuscular or subcutaneous injections are well tolerated although transitory inflammatory lesions without clinical impact can occur at the injection site.

May be used in pregnant and lactating cows and sows.

Special precautions for use in animals

Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevelance of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

Operator warnings

People with known hypersensitivity to fluoroquinolones should avoid using this product. Wash hands after use.

Pharmaceutical precautions

Do not store above 25°C and protect from light.

Following withdrawal of the first dose, use the product within 28 days. Any unused material should be discarded.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Manure and slurry containing marbofloxacin should not be spread on the same area of land in successive years.

Legal category

POM-V

Packaging Quantities

Amber type II glass vials of 20, 50, 100 and 250ml. The vials are closed with a chlorobutyl rubber stopper oversealed within aluminium caps. Each vial is packaged in a cardboard box. Not all pack sizes may be marketed.

Further information

ATC Vet code: QJ01MA93

Pharmacodynamic properties:

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Citrobacter freundii, Enterobacter cloacae, Serratia marcescens, Morganella morganii, Proteus spp, Klebsiella spp, Shigella spp, Pasteurella spp, Haemophilus spp, Moraxella spp, Pseudomonas spp) as well as Mycoplasma spp.

Pharmacokinetic properties:

After subcutaneous or intramuscular administration in cattle and intramuscular administration in pigs at the recommended dose of 2mg/kg, marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5microgram/ml within less than 1 hour. Its bioavailability is close to 100%. It is weakly bound to plasma proteins (less than 10% in pigs and 30% in cattle), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, uterus, digestive tract) it achieves a higher concentration than in plasma.

In cattle, marbofloxacin is eliminated slowly in pre-ruminating calves (t1/2β = 5-9h) but faster in ruminant cattle (t1/2β = 4-7h) predominantly in the active form in urine (¾ in pre-ruminating calves, ½ in ruminants) and faeces (¼ in pre-ruminating calves, ½ in ruminants).

In pigs, marbofloxacin is eliminated slowly (t1/2β = 8-10h) predominantly in the active form in urine (2/3) and faeces (1/3).

Marketing Authorisation Holder (if different from distributor)

Vetoquinol SA

Magny-Vernois

BP 189

70204 Lure

Cedex

France

Marketing authorisation number

Vm 06462/4003.

GTIN (Global Trade Item No)

Marbocyl 10% 50ml

03605870006359

Marbocyl 10% 100ml

03605870006366

Marbocyl™ 2% Solution for Injection

Presentation

Marbocyl 2% is presented as a sterile solution for injection.

Marbofloxacin 2.0% w/v

Disodium edetate 0.01% w/v

Thioglycerol 0.05% w/v

Metacresol 0.2% w/v

Uses

In pre-ruminant cattle up to 100kg bodyweight and pigs, Marbofloxacin 2 % is indicated in the treatment of respiratory infections caused by susceptible strains of organisms.

Dosage and administration

The recommended dosage is 2 mg/kg/day (1 ml/10 kg) in a single daily injection by subcutaneous or intravenous routes in cattle and by the intramuscular route in pigs.

Treatment duration is 3 - 5 days by the intravenous route in cattle, 3 days by the subcutaneous route in cattle, and 3 - 5 days by the intramuscular route in pigs.

The volume of injection should be limited to 10ml at each site of injection for pigs.

In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.

Contra-indications, warnings, etc

Special Precautions for use in Animals

Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Wherever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

No severe side-effects are to be expected at doses up to 5 times the recommended dose in cattle and pigs. In particular no lesions of the articular joints are encountered.

Subcutaneous injection is well tolerated. Transitory inflammatory reactions are sometimes observed at the injection site, but without clinical impact.

Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.

Operator Warning

People with known hypersensitivity to fluoroquinolones should avoid using this product. Wash hands after use.

Withdrawal periods

Preruminating calves (up to 100kg bodyweight): 6 days

Pigs: 4 days

Pharmaceutical precautions

Following withdrawal of the first dose, use the product within 28 days. Discard unused material.

Do not store above 25°C. Protect from light.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Manure and slurry containing marbofloxacin should not be spread on the same area of land in successive years.

Legal category

POM-V

Packaging Quantities

Packaged in amber type II glass vials of 10, 20, 50ml, 100 ml and 250ml.

The vials are closed with a chlorobutyl rubber stopper oversealed with aluminium caps.

Each vial is packaged in a cardboard box.

Not all pack sizes may be marketed.

Further information

ATC Vet Code: QJ01MA93

Pharmacodynamic properties

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Campylobacter jejunii, Citrobacter, Enterobacter, Proteus spp, Klebsiella spp Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella haemolytica, Pasteurella multocida, Haemophilus spp, Moraxella spp, Pseudononas aeruginosa) as well as Mycoplasma (Mycoplasma bovis, Mycoplasma dispar, Mycoplasma hyopneumoniae).

Resistance to Streptococcus may occur.

Pharmacokinetic properties

After subcutaneous administration in cattle and pigs at the recommended dose of 2 mg/kg, marbofloxacin is readily absorbed and its bioavailability is close to 100 %. It is weakly bound to plasma proteins (less than 10 % in pigs and 30 % in cattle), extensively distributed and, in most tissues (liver, kidney, skin, lung, bladder, uterus, digestive tract), it achieves higher concentrations than in plasma.

In cattle, marbofloxacin is eliminated slowly in pre-ruminating calves (t1/2β = 5-9 h) predominantly in the active form in urine (3/4) and faeces (1/4).

In pigs, marbofloxacin is eliminated slowly (t1/2β = 8-10 h) predominantly in the active form in urine (2/3) and faeces (1/3).

Marketing Authorisation Holder (if different from distributor)

Vetoquinol SA

Magny-Vernois

BP 189

70204 Lure

Cedex

France

Marketing authorisation number

Vm 06462/4005.

GTIN (Global Trade Item No)

Marbocyl 2%

03605870007387

Marbocyl™ Bolus 50 mg Tablet

Presentation

Each Marbocyl Bolus 50mg Tablet contains:

Marbofloxacin	50.00mg

Uses

Marbofloxacin bolus is indicated in the treatment of neonatal gastro-enteritis caused by Escherichia coli, in calves of 25-50kg.

Dosage and administration

The recommended dosage is 1mg/kg/day (1 bolus per 50kg calf) in a single oral administration per day.

Treatment duration is 3 days.

The bolus can be given manually or with an appropriate applicator.

Contra-indications, warnings, etc

Do not exceed the recommended duration of treatment (3 days).

When administration is carried out using an applicator, care should be taken to avoid soft tissue injury.

Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

At the recommended dosage, no undesirable effect is expected. At twice the dosage, a reversible, short term decrease of the intestinal Enterobacteriaceae population can occur, as well as faecal softening, but this is without clinical consequence as the balance of aerobes/anaerobes is not affected.

A greenish coloration of the faeces is sometimes observed, but this is reversible when the treatment is discontinued.

Concurrent administration of oral preparations which contain a high proportion of divalent cations may reduce marbofloxacin activity.

At four times the recommend dosage, a marked, reversible decrease in the intestinal Enterobacteriaceae population was observed. Diarrhoea can occur at higher dosages, as is known to occur for other oral antibiotics administered to neonatal animals. Further administration of marbofloxacin must be stopped and symptomatic treatment instituted.

Operator warning

People with known hypersensitivity to fluoroquinolones should avoid using this product. Wash hands after use.

Withdrawal periods

Meat: 6 days.

The product is not indicated for use in lactating animals.

Pharmaceutical precautions

Do not store above 25°C.

Keep out of reach of children.

For animal treatment only.

Any unused product or waste material should be disposed of in accordance with national requirements.

Legal category

POM-V

Packaging Quantities

Marbocyl Bolus is packaged in thermoshaped blister packs made of orange-yellow polyvinylchloride (PVC) and aluminium.

The product is supplied in a box containing 24 and 96 blisters of 6 boluses.

Further information

Pharmacodynamic properties

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. Fluoroquinolones act by concentration-dependent killing mechanism, so high plasma concentration initially is important (see below). It is effective against a wide range of Gram positive bacteria (in particular Staphylococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Campylobacter jejunii, Citrobacter freundii, Enterobacter cloacae, Serratia marcescens, Morganella morganii, Proteus spp, Klebsiella spp, Shigella spp, Actinobacillus pleuropneumoniae, Bordetella brochiseptica, Pasteurella haemolytica, Pasteurella multocida, Haemophilus spp, Moraxella spp, Pseudomonas spp, Brucella canis) as well as Mycoplasma (Mycoplasma bovis, Mycoplasma dispar, Mycoplasma hyopneumoniae). The bactericidal activity of marbofloxacin is concentration dependant on Gram–negative strains and time dependant on Gram-positive strains.

Pharmacokinetic properties

After oral administration to calves at the recommended dose of 1mg/kg, marbofloxacin is quite slowly absorbed and its bioavailability is close to 100%. It is weakly bound to plasma proteins (about 30% in calves), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, digestive tract) it achieves higher concentrations than in plasma.

After an oral administration, marbofloxacin is eliminated slowly in calves (t1/2β = 8.50 ± 2.88h) predominately in urine (72-81%) and faeces (5-13%) and in active form.

Marketing authorisation number

Vm 08007/4073.

GTIN (Global Trade Item No)

Marbocyl Bolus 24

03605870007615

Marbocyl Bolus 96

03605870007622

Marbocyl™ Solo 10% Solution for injection for cattle

Presentation

Solution for injection. Each ml contains 100mg marbofloxacin, disodium edetate 0.1mg, thioglycerol 1.0mg and metacresol 2.0mg.

Uses

Treatment of respiratory infections caused by sensitive strains of Pasteurella multicida, Mannheimia haemolytica and Histophilus somni in cattle.

Dosage and administration

The recommended dosage is 8 mg/kg body weight i.e. 2 ml /25kg body weight in a single intramuscular injection

If the volume to be injected is more than 20 ml, it should be divided between two or more injection sites.

Contra-indications, warnings, etc

Do not use in animals with known hypersensitivity to fluoroquinolones

Do not use in cases where the pathogen involved is resistant to other fluoroquinolones (cross resistance).

i)Special precautions for use in animals

Official and local antimicrobial policies should be taken into account when the product is used.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.

Whenever possible, fluoroquinolones should only be used based on susceptibility testing.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

ii)Special precautions to be taken by the person administering the medicinal product to animals.

People with known hypersensitivity to quinolones should avoid any contact with the product.

If the product comes into contact with the skin or eyes, rinse with copious amounts of water.

Accidental self-injection can induce a slight irritation.

Adverse reactions (frequency and seriousness)

Fluoroquinolones are known to induce arthropathies. Nevertheless, this effect has never been observed with marbofloxacin in cattle.

Administration by the intramuscular route may cause transient local reactions such as pain and swelling at the injection site and inflammatory lesions which may persist for at least 12 days after injection. No other adverse effect was observed on cattle.

Use during pregnancy and lactation

Laboratory studies in rats and rabbits have not produced any evidence of a teratogenic, embryotoxic or maternotoxic effect associated with the use of marbofloxacin. Safety of the product at 8 mg/kg has not been determined in pregnant cows or in suckling calves when used in cows. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

Overdose

No sign of overdosage has been observed after administration of 3 times the recommended dose. Overdosage may cause signs such as acute neurological disorders which should be treated symptomatically.

Withdrawal periods

Meat and offal: 3 days

Milk: 72 hours

Incompatibilities

Do not mix with other medicinal products.

Pharmaceutical precautions

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

After first opening the immediate packaging: 28 days

Protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements

Legal category

POM-V

Packaging Quantities

Details of the primary packaging:

Amber type II glass vials

Type I chlorobutyl rubber stopper

Presentations:

Carton containing one 50 ml vial

Carton containing one 100 ml vial

Further information

ATC Vet code: QJ01MA93

Pharmacotherapeutic group: anti-infectives for systemic use

Pharmacodynamic properties

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group, which acts by inhibition of DNA gyrase. It has a broad-spectrum activity in vitro against Gram-positive and Gram-negative bacteria.

The marbofloxacin in vitro activity against pathogens isolated in 2004 from bovine respiratory diseases during a clinical field trial in France, Germany, Spain and Belgium, is good: MIC values are comprised between 0.015 and 0.25 µg/ml for M.haemolytica (MIC 90 = 0.124 µg/ml; MIC50 = 0.025 µg/ml), between 0.004 and 0.12 µg/ml for P. multocida (MIC90 = 0.022 µg/ml; MIC50 = 0.009 µg/ml),and between 0.015 and 2 µg/ml for Histophilus somni. Strains with MIC <= 1 µg/ml are sensitive to marbofloxacin whereas strains with MIC >= 4 µg/ml are resistant to marbofloxacin.

Resistance to fluoroquinolones occurs by chromosomal mutation with three mechanisms: decrease of the bacterial wall permeability, expression of efflux pump or mutation of enzymes responsible for molecule binding.

Pharmacokinetic particulars

After a single intramuscular administration in cattle at the recommended dose of 8 mg/kg, the maximum plasma concentration of marbofloxacin (Cmax) is 7.3 µg/ml reached in = 0.78h (Tmax). Binding to plasma proteins is about 30%. Marbofloxacin is eliminated slowly

(T1/2β = 15.60 h), predominantly in the active form in urine and faeces.

Marketing authorisation number

Vm 08007/4118.

GTIN (Global Trade Item No)

Marbocyl Solo

03605874041547

Marbocyl P 5mg, 20mg and 80mg Tablets

Presentation

Beige brown spotted round tablets

Three strengths are available.

Marbocyl P 5 mg containing 5 mg marbofloxacin. For use in dogs and cats.

Marbocyl P 20 mg containing 20 mg marbofloxacin.For use in dogs.

Marbocyl P 80 mg containing 80 mg marbofloxacin. For use in dogs.

Uses

In Dogs

Marbocyl is indicated in the treatment of skin and soft tissue infections (skin fold pyoderma, impetigo, folliculitis, furunculosis, cellulitis), for the treatment of urinary tract infections associated or not with prostatitis and respiratory tract infections, caused by susceptible strains of organisms.

In Cats (Marbocyl P 5mg Tablet only)

Marbocyl is indicated for the treatment of skin and soft tissue infections (wounds, abscesses, phlegmons) and upper respiratory tract infections caused by susceptible strains of organisms.

Dosage and administration

For oral administration. The recommended dose rate is 2 mg/kg per day in a single daily administration. To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing.

In dogs for the treatment of skin and soft tissue infections, treatment duration is at least five days. Depending on the course of the disease it may be extended up to 40 days. In urinary tract infections, treatment duration is at least 10 days. Depending on the course of the disease it may be extended up to 28 days. In respiratory infections, treatment duration is at least 7 days and, depending on the course of the disease, may be extended up to 21 days.

In cats for the treatment of skin and soft tissue infections, treatment duration is 3–5 days. For upper respiratory infections, treatment duration is 5 days.

Contra-indications, warnings, etc

Marbofloxacin should not be used in dogs aged less than 12 months or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs with a longer growth period. Not recommended for use in cats aged less than 16 weeks.

Not suitable for infections resulting from strict anaerobes, yeast or fungi.

Do not use Marbocyl P 20mg or Marbocyl P 80mg tablets in cats. For the treatment of this species the Marbocyl P 5mg tablet is available.

Special precautions for use in animals

The fluoroquinolones have been shown to induce erosion of articular cartilage in juvenile dogs and care should be taken to dose accurately, especially in young animals.

The fluoroquinolones are known for their potential neurological side effects; cautious use is recommended in dogs and cats diagnosed as suffering from epilepsy.

A low urinary pH could have an inhibitory effect on the activity of marbofloxacin.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly to other classes of antimicrobials. Whenever possible, use of fluoroquinolones should be based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease effectiveness of treatment with other quinolones due to the potential for cross resistance.

Adverse reactions (frequency and seriousness)

At the therapeutic recommended dosage no severe side effects are to be expected in cats and dogs. In particular no lesions of the articular joints were encountered in clinical studies at the recommended dose rate.

Mild side effects such as vomiting, softening of faeces, modification of thirst or transient increase in activity may occasionally occur. These signs cease spontaneously after treatment and do not necessitate cessation of the treatment.

Use during pregnancy and lactation

Studies in pregnant rats and rabbits showed no side effects on pregnancy. However, no specific studies have been carried out in pregnant cats and dogs.

Interaction with other medicinal products and other forms of interaction

Fluoroquinolones are known to interact with orally administered cations (Aluminium, Calcium, Magnesium, Iron.) In such cases, the bioavailability may be reduced.

Overdose (symptoms, emergency procedures, antidotes), if necessary

Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.

Withdrawal period(s)

Not applicable

Operator warning

People with known hypersensitivity to fluoroquinolones should avoid using this product. In case of accidental ingestion seek medical attention and show product label and/or package leaflet to the doctor. Wear gloves when handling or dividing tablets. Wash hands after use.

Pharmaceutical precautions

No special precautions for storage.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category

POM-V

Packaging Quantities

Marbocyl P tablets are packaged in aluminium/aluminium blister packs.

Marbocyl P 5mg 10 blisters of 10 tablets

Marbocyl P 20mg 10 blisters of 10 tablets

Marbocyl P 80mg 12 blisters of 6 tablets

Further information

Pharmacodynamic properties

Marbofloxacin is a synthetic bactericidal antimicrobial belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci, Streptococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Citrobacter freundii, Enterobacter cloacae, Serratia marcescens, Morganella morganii, Proteus spp, Klebsiella spp, Shigella spp, Pasteurella spp, Haemophilus spp, Moraxella spp, Pseudomonas spp, Brucella canis) as well as Mycoplasma spp.

Marbofloxacin is not effective against anaerobes, yeasts or fungi.

Resistance to fluoroquinolones occurs by chromosomal mutation with three mechanisms: decrease of the bacterial wall permeability, expression of the efflux pump or mutation of the enzymes responsible for molecule binding. No significant evolution of resistance to marbofloxacin has been observed in the target pathogenic strains isolated from companion animals since the launch of the molecule on the veterinary market. The occurrence and rate of transfer of a genetic resistance is therefore considered to be very low.

Cross-resistance with ß-lactam antibiotics, aminoglycosides, tetracyclines, macrolide and polypeptide antibiotics, sulfonamides, diaminopyrimidines, and nitrofurans does not generally occur. However, certain mutations conferring resistance to fluoroquinolones can also confer resistance to cephalosporins, tetracyclines, macrolides and chloramphenicol.

Pharmacokinetic properties

After oral administration in dogs and cats at the recommended dose of 2 mg/kg, Marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5 µg/ml within 2 hours. Its bioavailability is close to 100%. It is weakly bound to plasma proteins (<10%), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, digestive tract) it achieves higher concentrations than in plasma. Marbofloxacin is eliminated slowly (t1/2β= 14h in dogs and 10h in cats) predominately in the active form, in urine (2/3) and faeces (1/3).

Marketing authorisation number

Marbocyl P 5 mg Vm08007/4109.

Marbocyl P 20 mg Vm08007/4110.

Marbocyl P 80 mg Vm08007/4111.

GTIN (Global Trade Item No)

Marbocyl P 5mg

03605877310220

Marbocyl P 20mg

03605877310312

Marbocyl P 80mg

03605877310497